CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Health’s Caremark business signed a new pharmacy benefits contract with the California Public Employees’ Retirement ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...